Role of MBD3-SOX2 axis in residual myeloma following pomalidomide
Leukemia, 2021•nature.com
Study design In order to study the biology of residual MM following Pom, MM cells were
exposed to the drug (100–300 ng/mL) or DMSO control in vitro and then utilized for
subsequent experiments with indicated doses equivalent to the therapeutic concentrations
achieved in vivo [6]. INA-6 cells xenografted into RGS6 mice [7] were utilized to study growth
of MM cells in vivo using the intra-femoral delivery of MM cells as described earlier
(Supplementary Fig. S1)[8]. Biospecimens obtained under the auspices of a clinical trial of …
exposed to the drug (100–300 ng/mL) or DMSO control in vitro and then utilized for
subsequent experiments with indicated doses equivalent to the therapeutic concentrations
achieved in vivo [6]. INA-6 cells xenografted into RGS6 mice [7] were utilized to study growth
of MM cells in vivo using the intra-femoral delivery of MM cells as described earlier
(Supplementary Fig. S1)[8]. Biospecimens obtained under the auspices of a clinical trial of …
Methods
Study design
In order to study the biology of residual MM following Pom, MM cells were exposed to the drug (100–300 ng/mL) or DMSO control in vitro and then utilized for subsequent experiments with indicated doses equivalent to the therapeutic concentrations achieved in vivo [6]. INA-6 cells xenografted into RGS6 mice [7] were utilized to study growth of MM cells in vivo using the intra-femoral delivery of MM cells as described earlier (Supplementary Fig. S1)[8]. Biospecimens obtained under the auspices of a clinical trial of pomalidomide (NCT01319422) in relapsed MM [9] were utilized to evaluate the effects of Pom on primary MM cells in vivo. All biospecimens were obtained following informed consent approved by Yale IRB and all animal studies were performed in accordance with protocols approved by Yale IACUC. Details of methods are noted under supplementary methods.
nature.com
